Retatrutide

Retatrutide is a next-generation triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Originally developed for metabolic research, it has shown significant potential in studies related to weight management and glucose regulation.

Available as: Lyophilised peptide, 10mg per vial

Key research highlights:

• Triple-action receptor activity (GLP-1 / GIP / Glucagon)

• Investigated for body composition and metabolic function

• High purity, research-grade compound

• Suitable for in vitro and laboratory use

Intended for research purposes only. Not for human consumption. For use by qualified researchers and professionals in controlled settings.

Store at -20°C. Handle with appropriate laboratory precautions.